

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

pAAV-CAG-FLuc

RRID:Addgene_83281

Type: Plasmid

Proper Citation

RRID:Addgene_83281

Plasmid Information

URL: <http://www.addgene.org/83281>

Proper Citation: RRID:Addgene_83281

Insert Name: Firefly Luciferase

Organism: Photinus pyralis (Firefly)

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:31723052](#)

Vector Backbone Description: Backbone Size:4721; Vector Backbone:pAAV with CAG promoter; Vector Types:Mammalian Expression, AAV; Bacterial Resistance:Ampicillin

Plasmid Name: pAAV-CAG-FLuc

Record Creation Time: 20220422T222539+0000

Record Last Update: 20260815T082103+0000

Ratings and Alerts

No rating or validation information has been found for pAAV-CAG-FLuc.

No alerts have been found for pAAV-CAG-FLuc.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Song Q, et al. (2025) Directed evolution of novel AAV variants using the MCMS library for enhanced CNS tropism and reduced liver targeting in mice. *Molecular therapy. Methods & clinical development*, 33(3), 101522.

Puzzo F, et al. (2024) AAV-mediated genome editing is influenced by the formation of R-loops. *bioRxiv : the preprint server for biology*.

Madigan V, et al. (2024) Human paraneoplastic antigen Ma2 (PNMA2) forms icosahedral capsids that can be engineered for mRNA delivery. *Proceedings of the National Academy of Sciences of the United States of America*, 121(11), e2307812120.

Jain NK, et al. (2024) Comprehensive mutagenesis maps the effect of all single-codon mutations in the AAV2 rep gene on AAV production. *eLife*, 12.

Gonzalez-Sandoval A, et al. (2023) The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner. *Nature communications*, 14(1), 2448.

Davis-Gardner ME, et al. (2023) A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors. *Frontiers in immunology*, 14, 1105617.

Puzzo F, et al. (2023) Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer. *Molecular therapy. Nucleic acids*, 31, 383.

Wu F, et al. (2023) Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. *Acta pharmaceutica Sinica. B*, 13(5), 2219.

Aaron KA, et al. (2023) Selection of viral capsids and promoters affects the efficacy of rescue of Tmprss3-deficient cochlea. *Molecular therapy. Methods & clinical development*, 30, 413.

Gardner MR, et al. (2022) High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes. *Molecular therapy. Methods & clinical development*, 24, 199.

Song R, et al. (2022) Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model. *Molecular therapy. Methods & clinical development*, 27, 73.

Mancuso P, et al. (2020) CRISPR based editing of SIV proviral DNA in ART treated non-human primates. *Nature communications*, 11(1), 6065.